XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Business Combinations [Abstract]        
Revenue $ 471 $ 220 $ 906 $ 220
Net loss (2,504) (2,111) (9,445) (10,162)
Net loss: Non-controlling interest (203) (136) (423) (476)
Net loss attributable to Heat Biologics, Inc. $ (2,301) $ (1,975) $ (9,022) $ (9,686)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.06) $ (0.10) $ (0.29) $ (0.61)